Article
Oncology
Xiangming Cai, Junhao Zhu, Jin Yang, Chao Tang, Feng Yuan, Zixiang Cong, Chiyuan Ma
Summary: The Ki-67 index is a useful indicator for predicting proliferation and aggressiveness in pituitary adenomas. This study developed and validated a predictive nomogram model to forecast Ki-67 index levels preoperatively in PAs. The nomogram included age, primary-recurrence subtype, maximum dimension, and prolactin as independent predictors associated with Ki-67 index levels, with stable predictive performance demonstrated in both the training and validation cohorts.
FRONTIERS IN ONCOLOGY
(2021)
Article
Neurosciences
Xuanzhi Wang, Mingwu Li, Xiaofeng Jiang, Fei Wang, Shiying Ling, Chaoshi Niu
Summary: The objective of this study was to investigate the factors influencing the prediction of the Ki-67 index in patients with pituitary adenomas (PAs). Data from 178 patients confirmed with PAs were retrospectively analyzed, and it was found that age, rich blood supply to the tumor, and erosion of the dorsum sellae bone were influencing factors for predicting the Ki-67 index. Suitable prediction models were developed and validated, providing potential for personalized treatment for PA patients.
Article
Oncology
N. Harbeck, P. Rastogi, M. Martin, S. M. Tolaney, Z. M. Shao, P. A. Fasching, C. S. Huang, G. G. Jaliffe, A. Tryakin, M. P. Goetz, H. S. Rugo, E. Senkus, L. Testa, M. Andersson, K. Tamura, L. Del Mastro, G. G. Steger, H. Kreipe, R. Hegg, J. Sohn, V Guarneri, J. Cortes, E. Hamilton, V Andre, R. Wei, S. Barriga, S. Sherwood, T. Forrester, M. Munoz, A. Shahir, B. San Antonio, S. C. Nabinger, M. Toi, S. R. D. Johnston, J. O'Shaughnessy
Summary: Adjuvant abemaciclib combined with endocrine therapy significantly improved invasive disease-free survival in patients with early breast cancer, with an acceptable safety profile. Ki-67 index was prognostic but did not affect the benefits of abemaciclib. The robust treatment benefit of abemaciclib extended beyond the planned 2-year treatment period.
ANNALS OF ONCOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Jiayi Bao, Yuanqing Liu, Xiaoxia Ping, Xinyi Zha, Su Hu, Chunhong Hu
Summary: This study aimed to establish a radiomics nomogram for preoperative prediction of the Ki-67 proliferation index in patients with stage T1a-b lung adenocarcinoma. The radiomics nomogram showed good predictive efficacy and can serve as a supplementary tool for clinicians in choosing appropriate treatment programs.
EUROPEAN JOURNAL OF RADIOLOGY
(2022)
Review
Oncology
Qixin Liu, Ziheng Peng, Liangfang Shen, Lin Shen
Summary: Ki-67 overexpression is associated with poor overall survival rates in melanoma patients, but not correlated with PFS and RFS rates. Ki-67 expression levels are associated with tumor thickness.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Matthew G. Davey, Sean O. Hynes, Michael J. Kerin, Nicola Miller, Aoife J. Lowery
Summary: In breast cancer development, the expression of Ki-67 is a valuable indicator for prognosis and treatment decision making. The advent of molecular medicine has transformed breast cancer management by recognizing the heterogeneity of the disease and using a combination of factors for substratification and personalization of treatment modalities. Routine evaluation of Ki-67 as a proliferation marker in breast cancer patients has limitations, but promising strategies are being explored to enhance its utility in future oncology.
Article
Multidisciplinary Sciences
Karim Mrouj, Nuria Andres-Sanchez, Geronimo Dubra, Priyanka Singh, Michal Sobecki, Dhanvantri Chahar, Emile Al Ghoul, Ana Bella Aznar, Susana Prieto, Nelly Pirot, Florence Bernex, Benoit Bordignon, Cedric Hassen-Khodja, Martin Villalba, Liliana Krasinska, Daniel Fisher
Summary: Ki-67, while not necessary for cell proliferation, plays a crucial role in tumor initiation, growth, and metastasis. Its absence leads to changes in the transcriptome and immune response, making cancer cells more susceptible to drugs and immune attacks.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Biochemistry & Molecular Biology
Yulin Fang, Yanjun Zhou
Summary: Today, using elastography and ultrasound images is the best method for diagnosing breast cancer for dense tissues, especially for women under 30 years old, which is used to detect the exact border of masses. Besides, using quantitative microscopic criteria that are less tasteful seems to be useful in predicting the behavior of the tumor and its prognosis. The proposed algorithm includes pre-processing, feature extraction, and classification, aiming to improve the accuracy of breast cancer diagnosis.
CELLULAR AND MOLECULAR BIOLOGY
(2023)
Article
Medicine, General & Internal
Yu Meng, Quan Quan, Fenfen Zhang, Yao Liu, Siling Ren, Xiaoling Mu
Summary: This study investigated the prognostic value of the Ki-67 index in endometrial stromal sarcoma and identified a cut-off value of 35% for predicting recurrence. High Ki-67 index and ovarian preservation were significantly associated with shorter progress free survival. The Ki-67 index could serve as a useful prognostic marker in endometrial stromal sarcoma.
FRONTIERS IN MEDICINE
(2022)
Review
Endocrinology & Metabolism
Antonio Bianchi, Sabrina Chiloiro, Antonella Giampietro, Simona Gaudino, Rosalinda Calandrelli, Ciro Mazzarella, Carmelo Caldarella, Mario Rigante, Marco Gessi, Liverana Lauretti, Laura De Marinis, Alessandro Olivi, Alfredo Pontecorvi, Francesco Doglietto
Summary: Growth hormone-secreting adenomas exhibit a wide range of behaviors and outcomes, from mild disease to aggressive neoplasms. Treatment for patients who do not respond to surgery or first-generation somatostatin receptor ligands may involve multiple surgical, medical, and radiation treatments. Currently, there are no markers that can predict the prognosis or aggressiveness of acromegaly. A multidisciplinary approach is necessary to tailor treatment for difficult/aggressive cases, including radiation therapy, chemotherapy, and emerging treatments.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Cell Biology
Koji Okudela, Tetsukan Woo, Yusuke Saigusa, Hiromasa Arai, Mai Matsumura, Hideaki Mitsui, Misaki Sugiyama, Motoki Sekiya, Yoshihiro Ishikawa, Hisashi Oshiro, Yoichi Kameda, Kenichi Ohashi
Summary: This study optimized a procedure for measuring the Ki-67 index in lung adenocarcinoma and established the best cut-off value. Using the SP6 antibody for immunohistochemical staining, they successfully developed an optimal procedure for determining the Ki-67 labeling index. They identified an optimal cut-off value of 0.12 and achieved a coverage probability >70% and a confidence interval of <0.05 in over 90% of cases.
Article
Endocrinology & Metabolism
Cristina Lamas, Rosa Camara, Carmen Fajardo, Pablo Remon-Ruiz, Betina Biagetti, Fernando Guerrero-Perez, Marta Araujo-Castro, Mireia Mora, Felicia Hanzu, Pedro Iglesias, Rogelio Garcia-Centeno, Alfonso Soto
Summary: In this retrospective study, temozolomide was found to be an effective medical treatment for aggressive pituitary neuroendocrine tumors and pituitary carcinomas, but may sometimes lead to tumor progression. Co-administration with radiotherapy may increase progression-free survival.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Emre Durcan, Fatma Ela Keskin, Hande Mefkure Ozkaya, Sabri Sirolu, Serdar Sahin, Ozge Polat Korkmaz, Nurperi Gazioglu, Necmettin Tanriover, Nil Comunoglu, Buge Oz, Osman Kizilkilic, Pinar Kadioglu
Summary: The expression levels of FGFR-4 in pituitary adenomas may serve as a marker for more aggressive tumor behavior. Patients without remission, with residual lesion, and T2-hyperintense adenoma had higher median H-scores for FGFR-4.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
(2022)
Article
Clinical Neurology
Sanjit Shah, Saima Manzoor, Yehudit Rothman, Matthew Hagen, Luke Pater, Karl Golnik, Abdelkader Mahammedi, Andrew L. L. Lin, Ruchi Bhabhra, Jonathan A. A. Forbes, Soma Sengupta
Summary: This is a case report highlighting the utility of immunotherapy in treating aggressive pituitary adenomas (APAs). The patient experienced complete resolution of recurrent APA and improved survival compared to the expected life expectancy. APAs are tumors with frequent recurrence and short median expected length of survival.
Article
Oncology
Yu Dai, Tingting Chen, Xinyue Li, Changning Zhang, Tingyuan Li, Yuqian Zhao, Yakun Wang, Simiao Chen, Lulu Yu, Mingyue Jiang, Zeni Wu, Jinghong Yang, Wen Chen
Summary: This study found that p16/Ki-67 dual staining showed variations in detecting cervical lesions between premenopausal and postmenopausal women. The accuracy and specificity of this test were higher in premenopausal women compared to postmenopausal women. For women with HR-HPV infection, especially premenopausal women, p16/Ki-67 performed better in identifying cervical CIN2/3 and ASC-US/LSIL lesions.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Letter
Gastroenterology & Hepatology
Sandra Faias, Susana Prazeres, Mario Cunha, Luisa Pereira, Ruben Roque, Paula Chaves, Marilia Cravo, Isabe Claro, Margarida Silveira, Valeriano Leite, Dias Pereira
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY
(2021)
Review
Endocrinology & Metabolism
Pedro Marques, Friso de Vries, Olaf M. Dekkers, Marta Korbonits, Nienke R. Biermasz, Alberto M. Pereira
Summary: Serum inflammation-based scores have been shown to be valuable in predicting the risk, clinical aggressiveness, disease outcomes, and prognosis in patients with endocrine tumors. Parameters such as the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio have been extensively investigated in this patient population.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Review
Endocrinology & Metabolism
Pedro Marques, Marta Korbonits
Summary: Pseudoacromegaly is a rare and heterogeneous group of conditions characterized by clinical features of acromegaly or gigantism, but without excess of GH or IGF-1. Establishing the underlying diagnosis can be challenging due to overlapping clinical features. Collaboration with clinical geneticists is crucial for the diagnosis of patients with genetic origins of pseudoacromegaly.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Pedro Marques, Sayka Barry, Eivind Carlsen, David Collier, Amy Ronaldson, Joan Grieve, Neil Dorward, Nigel Mendoza, Ramesh Nair, Samiul Muquit, Ashley B. Grossman, Marta Korbonits
Summary: NCAM expression does not differ significantly between PitNETs and normal pituitary, and is not associated with tumor invasiveness or proliferation. However, cytokines like CXCL10, CX3CL1, and FGF-2 may play a role in modulating NCAM expression in PitNETs.
JOURNAL OF NEUROENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Pedro Marques, Ana Luisa Silva, Dolores Lopez-Presa, Claudia Faria, Maria Joao Bugalho
Summary: The microenvironment of pituitary adenomas (PAs), consisting of non-tumoral cells and signaling molecules, plays a crucial role in tumor initiation, progression, and invasion. Recent studies have characterized immune and stromal cell populations, as well as various cytokines, chemokines, and growth factors in PAs. Key genes and immune-related molecules and pathways have also been investigated, with immune checkpoint regulators showing promise as targets for immunotherapy. Understanding the microenvironment of PAs provides insights into the complex biology of PAs and has implications for diagnosis, clinical management, and treatment of aggressive and refractory PAs.
Review
Cell Biology
Carolina Peixe, Miriam Sanchez-Garcia, Ashley B. Grossman, Marta Korbonits, Pedro Marques
Summary: When evaluating the somatotroph axis, it is important to consider the discrepancies in GH and IGF-1 levels in patients with acromegaly. These discrepancies may be due to early or partially treated disease, as well as other non-acromegaly causes such as pre-analytical and technical issues, physiological circumstances, and pathological conditions.
GROWTH HORMONE & IGF RESEARCH
(2022)
Letter
Endocrinology & Metabolism
Joao Roque, Pedro Marques
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM
(2022)
Letter
Medicine, General & Internal
Maria Ines Alexandre, Pedro Miguel Garrido, Pedro Marques
ACTA MEDICA PORTUGUESA
(2022)
Review
Cell Biology
Joao Roque, Pedro Marques
Summary: CVG is a rare benign skin lesion characterized by thickened and folded scalp, resembling the brain gyri and sulci. In acromegaly, CVG appears to be driven by the trophic effects of GH and IGF-1 on skin and soft tissues. Controlling the serum levels of GH and IGF-1 is essential for the management of acromegaly-related CVG.
GROWTH HORMONE & IGF RESEARCH
(2022)
Letter
Medicine, General & Internal
Ines Cosme, Pedro Marques, Maria Joao Bugalho
Article
Endocrinology & Metabolism
Sara Lomelino Pinheiro, Pedro Miranda Afonso, Ines Lemos Damasio, Joana Simoes-Pereira, Tiago Nunes da Silva, Valeriano Leite
Summary: The clinical relevance of solid/trabecular (ST) growth in papillary thyroid carcinoma (PTC) is unclear. This study found that ST growth in PTC was associated with larger tumor size and increased frequency of vascular invasion, but had no significant impact on patient prognosis in the absence of vascular invasion.
CLINICAL ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Carolina Peixe, Maria Ines Alexandre, Ana Raquel Gomes, Ema Nobre, Ana Luisa Silva, Tiago Oliveira, Dolores Lopez-Presa, Claudia C. Faria, Jose Miguens, Maria Joao Bugalho, Pedro Marques
Summary: A clinicopathological classification is useful in predicting the challenging disease course and treatment approach for patients with pituitary adenomas. Grade 2b tumors are more likely to require complex multimodal treatment and have higher rates of active disease at last follow-up.
Review
Endocrinology & Metabolism
P. Marques, M. Korbonits
Summary: The pituitary tumour microenvironment consists of various non-tumoural cells and signaling peptides, which can influence the behavior and development of pituitary tumours. Recent research has focused on immune and stromal cell subpopulations infiltrating pituitary tumours, as well as immune- and microenvironment-related pathways. Understanding the pituitary tumour microenvironment can improve the diagnosis and management of patients with aggressive or recurrent tumours.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
(2023)
Review
Oncology
Pedro Marques
Summary: Limited options are available for patients with aggressive or metastatic pituitary neuroendocrine tumours (PitNETs). Peptide receptor radionuclide therapy (PRRT), commonly used for gastroenteropancreatic neuroendocrine tumours, is being considered as a potential treatment for aggressive or metastatic PitNETs when other approaches fail. However, there is limited data on the use of PRRT in this context, mostly derived from case reports or small case series. This review examines the effectiveness and safety of PRRT in managing aggressive or metastatic PitNETs, as well as its effects on pituitary function in other cancer patients.
Article
Endocrinology & Metabolism
Daniela Dias, Ines Damasio, Pedro Marques, Helder Simoes, Ricardo Rodrigues, Branca Maria Cavaco, Valeriano Leite
Summary: This case report highlights the potential efficacy of GEMOX chemotherapy in patients with advanced follicular thyroid carcinoma resistant to multikinase inhibitors. The durable response to GEMOX significantly extended the overall survival of the patient.
EUROPEAN THYROID JOURNAL
(2023)